Abnormal transport along the lysosomal pathway in Mucolipidosis, type IV disease

  1. Chii-Shiarng Chen*,
  2. Gideon Bach, and
  3. Richard E. Pagano*,
  1. *Department of Biochemistry and Molecular Biology, Thoracic Diseases Research Unit, Mayo Clinic and Foundation, 200 First Street S.W., Rochester, MN 55905-0001; and Department of Human Genetics, Hadassah University Hospital, Jerusalem, Israel
  1. Edited by Elizabeth F. Neufeld, University of California, Los Angeles, School of Medicine, Los Angeles, CA, and approved April 1, 1998 (received for review September 30, 1997)

Abstract

Mucolipidosis, type IV (ML-IV) is an autosomal recessive storage disease that is characterized by lysosomal accumulation of sphingolipids, phospholipids, and acid mucopolysaccharides. Unlike most other storage diseases, the lysosomal hydrolases participating in the catabolism of the stored molecules appear to be normal. In the present study, we examined the hypothesis that the ML-IV phenotype might arise from abnormal transport along the lysosomal pathway. By using various markers for endocytosis, we found that plasma membrane internalization and recycling were nearly identical in ML-IV and normal fibroblasts. A fluorescent analog of lactosylceramide (LacCer) was used to study plasma membrane lipid internalization and subsequent transport. Lipid internalization at 19°C was similar in both cell types; however, 40–60 min after raising the temperature to 37°C, the fluorescent lipid accumulated in the lysosomes of ML-IV cells but was mainly concentrated at the Golgi complex of normal fibroblasts. Biochemical studies demonstrated that at these time points, hydrolysis of the lipid analog was minimal (∼7%) in both cell types. A fluorescence ratio imaging assay was developed to monitor accumulation of fluorescent LacCer in the lysosomes and showed that the apparent concentration of the lipid increased more rapidly and to a greater extent in ML-IV cells than in normal fibroblasts. By 60 min, LacCer apparently decreased in the lysosomes of normal fibroblasts but not in ML-IV cells, suggesting that lipid efflux from the lysosomes was also impaired. These results demonstrate that there is a defect in ML-IV fibroblasts that affects membrane sorting and/or late steps of endocytosis.

Footnotes

  • To whom reprint requests should be addressed at: Mayo Clinic and Foundation, Guggenheim 621-C, 200 First Street S.W., Rochester, MN 55905-0001. e-mail: pagano.richard{at}mayo.edu.

  • This paper was submitted directly (Track II) to the Proceedings Office.

  • Abbreviations: BODIPY, boron dipyrromethene difluoride; C5-DMB-, N-[5-(5,7-dimethyl BODIPY)-1-pentanoyl]-; Cer, ceramide; HMEM, 10 mM 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid-buffered minimal essential medium (pH 7.4), without indicator; HRP, horseradish peroxidase; LacCer, lactosylceramide; ML-IV, mucolipidosis, type IV; R/G, ratio of red to green fluorescence; Tfn, transferrin.

« Previous | Next Article »Table of Contents